Shiota Y, Sato T, Ono T
Department of Clinical Research, Kure Kyosai Hospital.
Arerugi. 1993 Dec;42(12):1782-7.
Serum soluble intercellular adhesion molecule-1 (sICAM-1) levels were measured in 54 asthmatic patients and 32 healthy subjects by sandwich enzyme-linked immunosorbent assay. Serum sICAM-1 levels in the asthmatic patients not undergoing steroid therapy were significantly higher than those in the healthy subjects and those in the asthmatic patients undergoing steroid therapy (p < 0.01 and p < 0.001, respectively). Serum sICAM-1 levels in the asthmatic patients during attack were not significantly different from those in the patients in remission. We studied changes in serum ICAM-1 levels in 13 asthmatic patients in remission and during attack and found that serum ICAM-1 levels during attack were significantly higher than those in remission (p < 0.05). The origin of serum soluble ICAM-1 in asthmatic patients still remains unclear, but the up-regulated expression of ICAM-1 on the endothelium of the respiratory tract may contribute to the recruitment of eosinophils, neutrophils and lymphocytes to the airway in bronchial asthma.
采用夹心酶联免疫吸附测定法，对54例哮喘患者和32名健康受试者的血清可溶性细胞间黏附分子-1（sICAM-1）水平进行了检测。未接受类固醇治疗的哮喘患者血清sICAM-1水平显著高于健康受试者以及接受类固醇治疗的哮喘患者（分别为p<0.01和p<0.001）。哮喘发作期患者的血清sICAM-1水平与缓解期患者相比无显著差异。我们研究了13例哮喘缓解期和发作期患者血清ICAM-1水平的变化，发现发作期血清ICAM-1水平显著高于缓解期（p<0.05）。哮喘患者血清可溶性ICAM-1的来源尚不清楚，但呼吸道内皮细胞上ICAM-1表达上调可能有助于支气管哮喘中嗜酸性粒细胞、中性粒细胞和淋巴细胞向气道募集。
